Your browser doesn't support javascript.
loading
Efficacy of infantile hepatic hemangioma with propranolol treatment: A case report.
Tsai, Mu-Chieh; Liu, Hsi-Che; Yeung, Chun-Yan.
Affiliation
  • Tsai MC; Division of Gastroenterology and Hepatology, Department of Pediatrics, MacKay Children's Hospital.
  • Liu HC; Division of Hematology and Oncology, Department of Pediatrics, MacKay Children's Hospital, Taipei.
  • Yeung CY; Department of Medicine, MacKay Medical College, New Taipei City.
Medicine (Baltimore) ; 98(4): e14078, 2019 Jan.
Article in En | MEDLINE | ID: mdl-30681565
ABSTRACT
RATIONALE Hepatic hemangioma is rarely discovered during the infantile period. Although most of the cases are asymptomatic, some of them may suffer life-threatening situations. In this regard, early detection is mandatory for preventing the ominous consequences that might be culminated from the disease. PATIENT CONCERNS A 2-month-14-day-old female infant was found incidentally to have multiple hepatic lesions during a newborn ultrasound screen. She was born smoothly at term after a non-eventful pregnancy course. Physical examination was completely normal and postnatal vital signs were stable. DIAGNOSIS Infantile multiple hepatic hemangiomas. INTERVENTION High-resolution ultrasound and abdominal computer tomogram were conducted to confirm the diagnosis. Propranolol was started at the age of 3 months and 7 days old with an initial dosage of 1.5 mg/kg per day and increased gradually to 2.5 mg/kg per day. No obvious adverse effects were noted during the treatment course. Rapid clinical improvement with decreasing size was observed by ultrasound 10 days after the treatment. Eventually, hepatic lesions totally disappeared 4.5 months later. Propranolol in dosage of 2.5 mg/kg per day was continued until 6 months after the initial prescription.

OUTCOMES:

A period of 11-month follow-up revealed no evidence of recurrence of hemangiomas. LESSONS Early diagnosis and intervention are mandatory for infantile hepatic hemangiomas to prevent possible ominous consequences. Though the propranolol therapy protocol for the disease is still under developing, the current report strengthens the recommendation to use propranolol as the first-line medication for treating infantile hepatic hemangiomas.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Propranolol / Adrenergic beta-Antagonists / Hemangioma / Liver Neoplasms Type of study: Diagnostic_studies / Guideline / Screening_studies Limits: Female / Humans / Infant Language: En Journal: Medicine (Baltimore) Year: 2019 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Propranolol / Adrenergic beta-Antagonists / Hemangioma / Liver Neoplasms Type of study: Diagnostic_studies / Guideline / Screening_studies Limits: Female / Humans / Infant Language: En Journal: Medicine (Baltimore) Year: 2019 Type: Article